Yıl: 2016 Cilt: 8 Sayı: 3 Sayfa Aralığı: 288 - 297 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results

Öz:
Objective: Polycystic ovary syndrome (PCOS) is a common endocrine problem in adolescents with an increasing prevalence of 30%. Pursuing new biomarkers with high specificity and sensitivity in the diagnosis of PCOS in adolescents is currently an active area of research. We aimed to investigate the diagnostic value of anti-Müllerian hormone (AMH), insulin-like peptide-3 (INSL3), inhibin-A (INH-A), and inhibin-B (INH-B) in adolescents with PCOS and also to determine the association, if any, between these hormones and clinical/laboratory findings related with hyperandrogenism.Methods: The study group comprised 53 adolescent girls aged between 14.5 and 20 years who were admitted to our outpatient clinic with symptoms of hirsutism and/or irregular menses and diagnosed as having PCOS in accordance with the Rotterdam criteria. Twenty-six healthy peers, eumenorrheic for at least two years and body mass index-matched, constituted the controls. Fasting blood samples for hormones [luteinizing hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone-sulfate (DHEAS), androstenedione (D4-A), total/free testosterone (T/fT), sex hormone binding globulin (SHBG), AMH, INSL3, INH-A, INH-B] were drawn after an overnight fast. Results: In the PCOS group, 83% of the subjects were oligomenorrheic/amenorrheic and 87% had hirsutism. The LH, LH/FSH ratio, total T, fT, free androgen-index (FAI), DHEAS levels were significantly higher (p=0.005, p=0.042, p=0.047, p<0.001, p=0.007, p=0.014, respectively) and SHBG was significantly lower (p=0.004) in PCOS patients as compared to the controls. Although the INSL3 and INH-B levels showed no difference between the groups (p>0.05), AMH and INH-A levels were found to be significantly higher in the PCOS group compared to the controls (p<0.001, p<0.001, respectively). In multiple linear regression analysis, WC SDS (p=0.028), logD4-A (p=0.033), logSHBG (p=0.031), and total ovarian volume (p=0.045) had significant effects on AMH levels, and LH (p=0.003) cells in men (9). In women, it is synthesized in the ovary, particularly by the theca interna cells of antral follicles as well as by the corpora lutea and ovarian stroma, and INSL3 levels seem to reflect gonadal function (10,11). INSL3 levels are similar in prepubertal and postpubertal periods, but a significant increase is observed after pubertal onset (12). Some studies show that INSL3 expression appears on INH-A levels. In receiver-operating characteristic analysis, the cut-off values for AMH and INH-A were 6.1 ng/mL (sensitivity 81.1%) and 12.8 pg/mL (sensitivity 86.8%), respectively, to diagnose PCOS. When AMH and INH-A were used in combination, the sensitivity (96.2%) increased. Conclusion: INSL3 and INH-B were not found to have diagnostic value in adolescents with PCOS. On the other hand, it was shown that INH-A could be used as a new diagnostic biomarker in addition to AMH.
Anahtar Kelime:

Konular: Endokrinoloji ve Metabolizma Pediatri
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:1-29. Epub 2014 May 21
  • Hickey M, Sloboda DM, Atkinson HC, Doherty DA, Franks S, Norman RJ, Newnham JP, Hart R. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab 2009;94:3714-3720. Epub 2009 Jun 30
  • Hart R, Doherty DA, Mori T, Huang RC, Norman RJ, Franks S, Sloboda D, Beilin L, Hickey M. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011;95:2347-2353. Epub 2011 Mar 29
  • Isabel-Bouzas IC, Cader SA, Leao L, Kuschnir MC, Braga C. Menstrual cycle alterations during adolescence: early expression of metabolic syndrome and polycystic ovary syndrome. J Peadiatr Adolesc Gynecol 2014;27:335-341. Epub 2014 Sep 23
  • Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41-47.
  • İliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332- 3340. Epub 2013 Jun 17
  • Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab 2006;20:311-330.
  • Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-4592. Epub 2013 Oct 22
  • Foresta C, Bettella A, Vinanzi C, Dabrilli P, Meriggiola MC, Garolla A, Ferlin A. A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab 2004;89:5952- 5958.
  • Nichols N, Binta H, Fields PA, Drost M, Chang SM, Ivell R, Fields MJ. Immunohistochemical localization of relaxin-like factor/insulin-like peptide-3 in the bovine corpus luteum. Ann NY Acad Sci 2005;1041:506-509.
  • Bamberger AM, Ivell R, Balvers M, Kelp B, Bamberger CM, Riethdorf L, Löning T. Relaxin-like factor (RLF): a new specific marker for Leydig cells in the ovary. Int J Gynecol Pathol. 1999;18:163-168.
  • Hagen CP, Mieritz MG, Nielsen JE, Anand-Ivell R, Ivell R, Juul A. Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls. Fertil Steril 2015;103:780-786. Epub 2014 Dec 13
  • Irving-Rodgers HF, Bathgate RA, Ivell R, Domagalski R, Rodgers RJ. Dynamic changes in the expression of relaxin-like factor (INSL3), cholesterol side-chain cleavage cytochrome p450, and 3beta- hydroxysteroid dehydrogenase in bovine ovarian follicles during growth and atresia. Biol Reprod 2002;66:934-943.
  • Satchell L, Glister C, Bleach EC, Glencross RG, Bicknell AB, Dai Y, Anand-Ivell R, Ivell R, Knight PG. Ovarian expression of Insulin- Like Peptide 3 (INSL3) and its receptor (RXFP2) during development of bovine antral follicles and corpora lutea and measurement of circulating INSL3 levels during synchronized estrous cycles. Endocrinology 2013;154:1897- 1906. Epub 2013 Apr 1
  • Gambineri A, Patton L, Prontera O, Fanelli F, Ciampaglia W, Cognigni GE, Pagotto U, Pasquali R. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. J Endocrinol Invest 2011;34:685-691. Epub 2011 May 17
  • Pelusi C, Fanelli F, Pariali M, Zanotti L, Gambineri A, Pasquali R. Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. J Clin Endocrinol Metab 2013;98:1575-1582. Epub 2013 Aug 8
  • Pelusi C, Stancampiano M, Fanelli F, Parialli M, Gambineri A, Pasqualli R. Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? Eur J Obstet Gynecol Reprod Biol 2015;195:188-192. Epub 2015 Oct 30
  • de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update 2002;8:529-541.
  • Welt CK, Smith ZA, Pauler DK, Hall JE. Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle- stimulating hormone, and stage of follicle development. J Clin Endocrinol Metab 2001;86:2531-2537.
  • Torgac M, Kokcu A, Cetinkaya MB, Alper T, Malatyalioglu E. Do basal inhibin A and inhibin B levels have value in the diagnosis of polycystic ovary syndrome? Gynecological Endocrinology 2005:20:322-326.
  • Hauzman EE, Fancsovits P, Murber A, Rabe T, Strowitzki T, Papp Z, Urbancsek J. Luteal-phase inhibin A and follicular- phase inhibin B levels are not characteristic of patients with an elevated LH-to-FSH ratio. J Assist Reprod Genet 2006;23:141-147.
  • Anderson RA, Groome NP, Baird DT. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin Endocrinol (Oxf) 1998;48:577-584.
  • Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, Dewailly D. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000;73:972-977.
  • Pigny P, Desailloud R, Cortet-Rudelli C, Duhamel A, Deroubaix-Allard D, Racadot A, Dewailly D. Serum alpha- inhibin levels in polycystic ovary syndrome. Relationship to the serum androstenedione level. J Clin Endocrinol Metab 1997;82:1939-1943.
  • Tsiqkou A, Luisi S, De Leo V, Patton L, Gambineri A, Reis FM, Pasquali R, Petraglia F. High serum concentration of total inhibin in polycystic ovary syndrome. Fertil Steril 2008;90:1859-1863.
  • Segal S, Elmadjian M, Takeshiqe T, Karp S, Mercado R, Rivnay B. Serum inhibin A concentration in women with polycystic ovarian syndrome and the correlation to ethnicity, androgens and insulin resistance. Reprod Biomed Online. 2010;20:675-680. Epub 2010 Feb 10
  • Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Hum Reprod 1998;13:2693- 2698.
  • Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 1998;83:1730-1735.
  • Laven JS, Imani B, Eijkemans MJ, de Jong FH, Fauser BC. Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility. Hum Reprod 2001;16:1359-1364.
  • Welt CK, Taylor AE, Martin KA, Hall JE. Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. J Clin Endocrinol Metab 2002;87:5559- 5565.
  • Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol 2015;7:280-293.
  • Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu MM, Akın MA, Çoban D, Gökoğlu S, Baştuğ O. Body weight, length and head circumference at birth in a cohort of Turkish newborns. J Clin Res Pediatr Endocrinol 2012;4:132-139. Epub 2012 May 4
  • Unalan D, Senol V, Bayat M, Mazicioğlu MM, Ozturk A, Kurtoglu S, Hatipoglu N, Ustunbas HB. Change in waist circumference over 3 years in Turkish children and adolescents. Ann Hum Biol 2013;40:419-425. Epub 2013 May 21
  • Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
  • Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:779-786.
  • Gordis L. Assessing the Validity and Reliability of Diagnostic and Screening Tests. In: Gordis L (ed). Epidemiology. Philadelphia, Elselvier Saunders, 2014:88-116.
  • Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
  • Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity (Silver Spring) 2013;21:1690-1694. Epub 2013 Apr 13
  • Galuzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008;18:511-518. Epub 2008 Jul 25
  • Cortet-Rudelli C, Pigny P, Decanter C, Leroy M, Maunoury- Lefebvre C, Thomas-Desrousseaux P, Dewailly D. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome. Fertil Steril 2002;77:281- 287.
  • Dursun F, Güven A, Yıldız M. Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome. J Clin Res Pediatr Endocrinol 2016;8:55-60. Epub 2015 Jan 18
  • Pawelczak M, Kenigsberg L, Milla S, Liu YH, Shah B. Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship toultrasound features. J Pediatr Endocrinol Metab 2012;25:983-989.
  • Cassar S, Teede HJ, Moran LJ, Joham AE, Harrison CL, Strauss BJ, Stepto NK. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf) 2014;81:899-906. Epub 2014 Sep 1
  • Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, Sloboda DM. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010;94:1118-1121. Epub 2010 Jan 8
  • Deveer M, Deveer R, Basaran O, Turkcu UO, Akbaba E, Cullu N, Turhan N, Kucuk M, Kasap B. Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome. J Clin Med Res 2015;7:989- 994. Epub 2015 Oct 23
  • Pinola P, Morin-Papunen LC, Bloiqu A, Puukka K, Ruokonen A, Järvelin MR, Franks S, Tapanainen JS, Lashen H. Anti- Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population- based cohort study. Hum Reprod 2014;29:2317-2325. Epub 2014 Jul 23
  • Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:238-243.
  • Anand-Ivell R, Tremellen K, Dai Y, Heng K, Yoshida M, Knight PG, Hale GE, Ivell R. Circulating insulin-like factor 3 (INSL3) in healthy and infertile women. Hum Reprod 2013;28:3093-3102. Epub 2013 Sep 5
  • Groome NP, Illingworh PJ, O'Brien M, Cooke I, Ganesan TS, Baird DT, McNeilly AS. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf) 1994;40:717-723.
  • Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab 2000;85:3319- 3330.
APA YETİM ŞAHİN A, YETİM Ç, BAŞ F, BÜLENT EROL O, ÇIĞ G, Uçar A, DARENDELİLER F (2016). Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. , 288 - 297.
Chicago YETİM ŞAHİN AYLİN,YETİM Çağcıl,BAŞ Firdevs,BÜLENT EROL Oğuz,ÇIĞ Gülnaz,Uçar Ahmet,DARENDELİLER FATMA FEYZA Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. (2016): 288 - 297.
MLA YETİM ŞAHİN AYLİN,YETİM Çağcıl,BAŞ Firdevs,BÜLENT EROL Oğuz,ÇIĞ Gülnaz,Uçar Ahmet,DARENDELİLER FATMA FEYZA Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. , 2016, ss.288 - 297.
AMA YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. . 2016; 288 - 297.
Vancouver YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. . 2016; 288 - 297.
IEEE YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F "Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results." , ss.288 - 297, 2016.
ISNAD YETİM ŞAHİN, AYLİN vd. "Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results". (2016), 288-297.
APA YETİM ŞAHİN A, YETİM Ç, BAŞ F, BÜLENT EROL O, ÇIĞ G, Uçar A, DARENDELİLER F (2016). Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology, 8(3), 288 - 297.
Chicago YETİM ŞAHİN AYLİN,YETİM Çağcıl,BAŞ Firdevs,BÜLENT EROL Oğuz,ÇIĞ Gülnaz,Uçar Ahmet,DARENDELİLER FATMA FEYZA Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology 8, no.3 (2016): 288 - 297.
MLA YETİM ŞAHİN AYLİN,YETİM Çağcıl,BAŞ Firdevs,BÜLENT EROL Oğuz,ÇIĞ Gülnaz,Uçar Ahmet,DARENDELİLER FATMA FEYZA Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology, vol.8, no.3, 2016, ss.288 - 297.
AMA YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology. 2016; 8(3): 288 - 297.
Vancouver YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology. 2016; 8(3): 288 - 297.
IEEE YETİM ŞAHİN A,YETİM Ç,BAŞ F,BÜLENT EROL O,ÇIĞ G,Uçar A,DARENDELİLER F "Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results." Journal of Clinical Research in Pediatric Endocrinology, 8, ss.288 - 297, 2016.
ISNAD YETİM ŞAHİN, AYLİN vd. "Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results". Journal of Clinical Research in Pediatric Endocrinology 8/3 (2016), 288-297.